Glaxo announced at ASCO on Sunday that in a Phase III study<span style="font-size: 13px;">, Tykerb and Herceptin failed to improve </span>disease-free survival in HER2-positive early breast cancer patients over<span style="font-size: 13px;"> Herceptin on its own.</span>
written on 01.06.2014